Skip to main content
. 2024 Oct 13;23:3692–3701. doi: 10.1016/j.csbj.2024.10.013

Fig. 5.

Fig. 5

Time of addition study for Rilapladib: (A) Schematic diagram of the plaque assay performed by pre-treating the HCE cells with the drug for 24 h followed by HSV-1 infection for 24 h (B) Results shown for the pre-treatment of the drug as compared to DMSO treated (control) (C) Schematic diagram of the plaque assay performed for post-entry antiviral effect of the drug where the drug was added 2-hour post-infection and Plaque results are shown in (D).